[EN] FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 [FR] DÉRIVÉS DE 1,4-DIHYDRODIOXINE FUSIONNÉS À UTILISER EN TANT QU'INHIBITEURS DE FACTEUR DE TRANSCRIPTION 1 DU CHOC THERMIQUE
BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS
申请人:Allison Brett D.
公开号:US20100280240A1
公开(公告)日:2010-11-04
Antibacterial compounds, compositions containing them, and methods of use for the inhibition of bacterial activity and the treatment, prevention or inhibition of bacterial infection.
抗菌化合物,含有它们的组合物,以及用于抑制细菌活性和治疗、预防或抑制细菌感染的使用方法。
BICYCLIC PIRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS
申请人:Allison Brett D.
公开号:US20100274004A1
公开(公告)日:2010-10-28
Antibacterial compounds, compositions containing them, and methods of use for the inhibition of bacterial activity and the treatment, prevention or inhibition of bacterial infection.
抗菌化合物,含有它们的组合物以及使用方法,用于抑制细菌活动和治疗、预防或抑制细菌感染。
Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor I
申请人:Cancer Research Technology Limited
公开号:US10189821B2
公开(公告)日:2019-01-29
The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
本发明涉及本文定义的式 I 化合物。本发明的化合物是热休克因子 1(HSF1)的抑制剂。特别是,本发明涉及将这些化合物用作治疗剂来治疗和/或预防增殖性疾病,如癌症。本发明还涉及这些化合物的制备工艺以及包含这些化合物的药物组合物。
FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1
申请人:Cancer Research Technology Limited
公开号:EP3052492A1
公开(公告)日:2016-08-10
FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR I
申请人:Cancer Research Technology Limited
公开号:US20170037036A1
公开(公告)日:2017-02-09
The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.